---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-242617"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T09:03:36.302479+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biogen completes Reata acquisition; SKYCLARYS launch underway in U.S.

## Summary
- Acquired SKYCLARYS (omaveloxolone), first FDA-approved treatment for Friedreich's ataxia.
- Over 1,000 patient start forms submitted in the U.S. since launch; EU review ongoing.
- Deal expected slightly dilutive to Non-GAAP EPS in 2023, neutral in 2024, accretive from 2025.
- Biogen to update 2023 financial guidance with Q3 earnings release.

## SEC filing metadata
- accession: 0001193125-23-242617
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000119312523242617/0001193125-23-242617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000119312523242617/d487087d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-242617
- JSON: https://secwatch.observer/filing/0001193125-23-242617.json
- Plain text: https://secwatch.observer/filing/0001193125-23-242617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.